HFS Prior Approval Form for Synagis (pavilizumab) 2005-2006 Season

SYNAGIS PRIOR APPROVAL REQUEST FORM

A. PHYSICIAN INFORMATION ALL Information Requested On This Form Must Be Complete					
Physician Name:	DEA #:				
B. PHARMACY INFORMATION					
Pharmacy Name:	Pharmacy I.D. #:	Pharmacy Phone #:			
C. PATIENT INFORMATION					
Patient Name:	DOB/	Patient 9 digit IDPA Recipient Number:			
Gestational Age at Birth:	Diagnosis:	first season second season other			
Birth Weight: Current Unclothed We	eight (and date)*:	Dose: 15mg/kg = Nearest vial size: 50mg / 100mg			
D. PATIENT INFORMATION					
Infant born at 29 - 32 weeks gestation or earlier with birth date after April 1, 2005 Child born after October 1, 2003 with hemodynamically significant congenital heart disease Child born after October 1, 2003 with chronic lung disease requiring treatment within the last 6 months (define treatment in section E) Child born after October 1, 2001 requiring mechanical ventilation for lung disease Child born between 32 and 35 weeks gestation and is currently under 6 months of age with the following risk factors: (list below)					
E. NOTES:	ation along with this form or provide such information	below. If weight changes during the season, please indicate new weight and date below.			
important. 10 prevent delay, fax felevant patient informa	ation along with this form of provide such information	below. If weight changes during the season, please indicate new weight and date below.			
F. PHYSICIAN or DESIGNEE'S SIGNATURE:		Date:			

ILLINOIS HEALTHCARE AND FAMILY SERVICES SYNAGIS PRIOR APPROVAL ROUNDING CRITERIA

WEIGHT	DOSE	50mg Vial	100 mg Vial
RANGE - KG			
0 - 3.6 kg	0 - 54mg	1	
3.7 – 7.3 kg	55 - 109mg		1
7.4 - 10.6 kg	110mg – 159mg	1	1
10.7 – 14.0 kg	160 mg – 210 mg		2

The above reflects the most commonly dosed amounts. Doses above 210 mg. can be approved based upon child's weight.